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Estrogen metabolites in human
corpus luteum physiology:
differential effects on
angiogenic activity
Soledad Henríquez, Ph.D.,a Paulina Kohen, B.S.,a Xia Xu, Ph.D.,c Timothy D. Veenstra, Ph.D.,d
Alex Mu~noz, B.Sc.,a Wilder A. Palomino, M.D.,a,b Jerome F. Strauss III, M.D., Ph.D.,e and Luigi Devoto, M.D.a,b
a Institute for Maternal and Child Research, Santiago, Chile; b Department of Obstetrics and Gynecology, Faculty of
Medicine, San Borja-Arriaran Clinical Hospital, University of Chile, Santiago, Chile; c Research Technology Program,
Biomedical Research (formerly SAIC-Frederick), Frederick National Laboratory for Cancer Research, Frederick, Maryland;
d Maranatha Baptist University, Watertown, Wisconsin; and e Department of Obstetrics and Gynecology, School of
Medicine, Virginia Commonwealth University, Richmond, Virginia
Objective: To determine tissue concentrations of E2, estrone, P, and estrogensmetabolites (EMs) 2-methoxyestradiol, 2-methoxyestrone,
4-hydroxyestrone, and 16-ketoestradiol in corpus luteum (CL) of different ages, and after hCG administration; and to examine the effects
of EMs on vascular endothelial growth factor (VEGF) secretion and angiogenic activity released by cultured luteinizing granulosa cells in
the presence and absence of hCG.
Design: Experimental study.
Setting: University.
Patient(s): Thirty-two healthy women of reproductive age.
Intervention(s): Corpus luteum was collected at the time of minilaparotomy for tubal sterilization, at varying stages of the luteal phase
(LP). Late-LP CL was collected 24 hours after IM administration of 10,000 IU hCG. Granulosa cells were isolated from follicular aspirates
obtained from healthy women participating in our IVF program for male factor infertility.
Main Outcomes Measure(s): Estrogen metabolite concentrations were determined in CL tissue, and VEGF was assessed in conditioned
medium. The angiogenic activity was analyzed by bioassay.
Result(s): Concentrations of EMs with proangiogenic activity (16-ketoestradiol and 4-hydroxyestrone) were higher in early and mid-
LP CL vs. late-LP CL. These EMs and hCG increased VEGF production and angiogenic activity. Conversely, late-LP CL had significantly
higher levels of 2-methoxyestrone and 2-methoxyestradiol, which have antiangiogenic activity. Administration of hCG reduced the
production of these EMs.
Conclusion(s): Our findings suggest that the EMs are important paracrine modulators of CL function. Administration of hCG increases
the production of EMs with proangiogenic activity and reduces the secretion of those EMs with antiangiogenic action, suggesting a
novel mechanism by which the late-LP CL is rescued in conception cycles. (Fertil Steril 2016;106:230–7. 2016 by American
Society for Reproductive Medicine.)
Key Words: 2-Methoxyestradiol, 2-methoxyestrone, 16-ketoestradiol, 4-hydroxyestrone, human corpora lutea
Discuss: You can discuss this article with its authors and with other ASRM members at http://fertstertforum.com/henriquezs-
estrogen-metabolites-cl-angiogenesis/
T he human corpus luteum (CL), atemporary endocrine glandderived from the ovulated follicle, is the principal source of steroidhormones during the secretory phase ofthe human menstrual cycle. It produces a significant amount of P, androgens,and E2. After ovulation, LH pulsesplay a central role sustaining CL ste-
roidogenic function. A prominent char-
acteristic of early and mid-luteal phase
CL is the establishment of a rich
vascular network. This vascular devel-
opment facilitates access of lipopro-
teins that provide the cholesterol
substrate for steroid biosynthesis by lu-
teinized granulosa and theca cells.
Estradiol biosynthesis is dependent
upon androgens production by theca
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cells, followed by their aromatization by aromatase expressed
in human granulosa cells. This two-cell system of E2 biosyn-
thesis in the ovarian follicle is mimicked by theca lutein and
granulosa lutein cells of the CL (1).
Estradiol has luteolytic and luteotrophic functions in
different species, acting through genomic or nongenomic
pathways (2, 3). The expression of E2 receptors (ERa and
ERb) has been described in human and monkey CL (4–6). In
addition, 17b-hydroxysteroid dehydrogenase type 1 acts as
a reductase converting estrone (E1) into E2 in ovarian cells,
and it reaches its maximum expression just before the late
luteal phase. Thus, E2 may act as a paracrine regulator of
luteal function and CL life span (7). Interestingly, an
alternative form of E2 regulation of CL function may
involve nongenomic pathways. Previous studies from our
laboratory have suggested that E2 modulates P production
in human granulosa luteal cells through the inhibition of
3b-hydroxysteroid dehydrogenase activity (8). These
intracrine actions suggest that E2 regulates human luteal
cells function through multiple pathways. On the other
hand, the regression of the human CL includes functional
and structural changes, including a significant reduction in
P secretion and loss of the glandular vascular network (9,
10). Conversely, in the clinical setting the administration of
10,000 IU hCG to women during the mid-luteal and late luteal
phases results in a significant increase in plasma P secreted by
the CL, and an important reduction of biochemical markers of
cell death (11).
There has been increasing interest in the study of estro-
gens metabolites (EMs), and more specifically E2 metabolite
signaling pathways, mostly in estrogen-producing tissues
(12). Several of these compounds have proapoptotic and anti-
angiogenic activities (13, 14). Some of these compounds have
been tested as anticancer drugs (15). A recent publication
from our laboratory indicated that 2-methoxyestradiol
(2-ME2) in physiologic doses in vitro inhibits vascular endo-
thelial growth factor (VEGF) secretion by luteal cells. Interest-
ingly, 2-ME2 did not prevent hCG stimulation of P
biosynthesis by cultured luteinizing granulosa cells (LGCs)
(16). In addition, it is known that the human CL produces
other EMs, such as other catecholestrogens and keto-
estrogens, whose biological activity has not been studied in
human ovarian cells.
On the basis of our previous findings and the limited
understanding of the role of EMs in human luteal function,
the present study was undertaken to [1] assess E2, E1, and P
and the E2 metabolites 2-ME2, 2-methoxyestrone (2-ME1),
4-hydroxyestrone (4-OHE1), and 16-ketoestradiol (16-
ketoE2) in luteal tissue throughout the luteal phase, and after
hCG administration during the late luteal phase; and [2]
examine the effect of EMs on VEGF secretion and angio-
genic activity of cultured LGCs in the presence and absence
of hCG.
MATERIALS AND METHODS
Clinical and Surgical Trials
Corpus luteumwas collected by minilaparotomy from women
aged 30–33 years (n¼ 20) who requested surgical sterilization
at our institution. The participants were healthy, with normal
body mass index and regular menstrual cycles, and they had
not received any hormonal treatment for at least 3 months
before participating in the study. The surgical procedure
was scheduled at varying times during the luteal phase and
conducted as previously reported (17). The presumptive day
of ovulation was determined according to the menstrual
pattern, serial vaginal ultrasound, and urinary LH tests. Daily
visits of the participant to our outpatient clinic started when
the leading follicle reach 14 mm. The day of ovulation was
estimated 24 hours after the LH peak. Histologic criteria
were also used to confirm the age of the CL. The CL was clas-
sified as early CL, 3 to 4 days after LH peak, n¼ 5; mid-luteal
phase CL, 5 to 9 days after the LH peak, n ¼ 5; and late luteal
phase CL, 10 to 12 days after the LH peak, n ¼ 5. Late luteal
phase CL were stimulated with 10,000 IU of hCG 48 hours
before surgery, n ¼ 5.
The institutional review board of San Borja-Arriaran
Clinical Hospital approved the study, and written informed
consent was obtained from all women participating in the
study.
Laboratory Techniques
Tissue for histology and immunodetection was fixed in 4%
buffered paraformaldehyde and embedded in paraffin wax.
Other pieces of tissue were used for extraction of steroids,
or snap- frozen in liquid nitrogen and stored at 70C for
protein determination as described elsewhere (10).
LGC Cultures
Human LGCs were obtained from follicular aspirates of
healthy women participating in our IVF program because of
male factor infertility (n ¼ 12). The cells were obtained after
centrifugation of follicular fluid at 400  g for 5 minutes.
The pellet was suspended, and red blood cells and detritus
were removed using a Histopaque (Sigma-Aldrich) gradient.
Macrophages were eliminated by preplating for 30 minutes
at 37C, and cultures were completed as previously described
(18). The purity of LGCs in culture was assessed by immuno-
detection of the steroidogenic acute regulatory protein (StAR).
This protein it is expressed in GCs after the LH peak in normal
cycles or after hCG administration in ovarian stimulation cy-
cles (Supplemental Fig. 1).
Measurement of VEGF
Vascular endothelial growth factor was quantified in condi-
tioned medium (CM) of LGCs cultured for 24 hours under
basal conditions and in the absence and presence of hCG
(10 IU/mL) with 16-ketoE2 (0.05 mM; Sigma-Aldrich), 2-
ME1 (0.05 mM; Sigma-Aldrich), and 4-OHE1 (0.05 mM;
Sigma-Aldrich). Conditioned medium was stored at 20C.
Vascular endothelial growth factor was measured by ELISA
according to the protocol provided by R&D Systems. The
assay includes monoclonal antibody, and samples were as-
sayed in duplicate. The VEGF concentration was measured
at 450 nm of absorbance. The intra-assay coefficient of
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variation was 2.4%–10.2%; the interassay coefficient of vari-
ation was 5.1%–8.7%.
Analysis of EMs
Corpus luteum tissue (100 mg) was homogenized in 0.5 mL of
GPB (0.1% gelatin–0.01 M phosphate-buffered saline [pH
7.0]) using a Potter-Elvehjem homogenizer with a tight-
fitting Teflon pestle. Steroid extraction was performed with
3mL of ethyl acetate p.a. (Merck) containing 1% (vol/vol) ace-
tic acid with vortexing for 3 minutes. Tubes were centrifuged
(1,100  g) for 10 minutes. The pellet was frozen on dry ice,
and the ethyl acetate fraction was transferred to a clean glass
tube and evaporated to dryness under nitrogen as previously
reported (19). This procedure was performed twice.
The samples were quantified by high performance liquid
chromatography (HPLC) equipped with a diode array ultravi-
olet detector (Agilent), mass spectrometer detector model ZQ
MSD (Waters). Twenty microliters of sample was injected to
an auto sampler injector (LEAP Technologies) (19).
In Vitro Analysis of Angiogenic Activity
Angiogenic activity was determined in CM obtained from
granulosa–lutein cells cultured in the absence and presence
of hCG (10 UI/mL) and with and without 16-keto-E2
(0.05 mM), 2-ME1 (0.05 mM), and 4-OHE1 (0.05 mM) for
24 hours. EA.hy926 cells have maintained the phenotype of
endothelial cells and were obtained by hybridization of hu-
man umbilical vein endothelial cells with the A549/8 human
lung carcinoma cell line. The establishment of the EA.hy926
endothelial cell line was reported by, and cells kindly donated
by, Dr. Cora-Jean S. Edgell of the University of North Car-
olina. Cells were collected after trypsin treatment, and
40,000 cells were plated onto matrigel, in the presence of
500 mL of the different media under investigation.
EA.hy926 cells were periodically photographed and analyzed
using an inverted phase microscope as previously reported
(20). Ten representative images per well were recorded and
transferred to a computer for image analysis for quantifica-
tion of an in vitro angiogenic score (AS):
Western Blotting
Gel electrophoresis was performed by 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, and proteins
were transferred onto polyvinylidene difluoride (PVDF)
membranes (GE Healthcare) as previously reported (16).
After transfer, blots were incubated with either anti-
catechol-O-methyl transferase (COMT) primary antibody
(Sigma-Aldrich) diluted 1:500, or anti-cytochrome P450
1A1 (Millipore) diluted 1:3,000, or anti-b-actin (Sigma-Al-
drich) at 4C overnight. Horseradish peroxidase–conjugated
secondary antibody was used, and chemiluminescence was
detected using an Ultra Quant 6.2 Image Reader and
analyzed by Image Quant 5.2 software (Molecular Dy-
namic). Densitometric analysis of immnuoreactive bands
was normalized to b-actin.
Immunohistochemistry
A Histostain-SP Broad Spectrum kit (Invitrogen) was used
for immunostaining. The blocking of peroxidase activity
was carried out with 3% H2O2 in methanol after antigen
retrieval. Nonspecific binding was blocked, and washes
between each step were made with phosphate-buffered
saline. Sections with anti-VEGF (ab-4) rabbit pAb (Calbio-
chem) were incubated overnight at 4C and conjugated
with secondary biotinylated antibody and streptavidin–
horseradish peroxidase. To visualize bound antibodies,
aminoethilcarbazole was used. Images were captures with
a light microscope (Olympus BX-51, Olympus Optical)
equipped with a CoolSNAP-pro image capture system
(Media Cybernetics).
Statistical Analysis
Data are presented as means  SEM. One-way analysis of
variance was performed, followed by a Newman-Keuls test.
GraphPad Prism (GraphPad Software) was used to analyze
data. Significance was defined as P< .05.
RESULTS
Luteal Tissue Concentration of Steroid Hormones
and EMs
Figure 1 shows the tissue concentrations of E1, E2, and P in
the CL throughout the luteal phase and after administration
of a single IM dose of 10,000 IU of hCG. The levels of es-
trogens and P show similar trends during the study period.
The highest luteal tissue concentrations of E1 and E2 were
observed in mid-luteal phase CL. However, values were
significantly different only for E1 compared with the late
luteal phase (1.59  0.4 vs. 0.5  0.15, P%.01). Human
chorionic gonadotropin did not increase significantly the
tissue levels of E1 and E2 as compared with late CL (n ¼
5) (Fig. 1A and B). Exogenous hCG increased significantly
the concentration of P in regressing CL (Fig. 1C). 2-
Methoxyestradiol was the most abundant methoxyestrogen
in the luteal tissue. The lowest levels of 2-ME2 and 2-ME1
were detected in mid-luteal phase CL (P< .05), followed by
a significant increase in late luteal phase CL. Interestingly,
hCG administration significantly reduced 2-ME2 and
AS ¼
ðNo of sprouting cellsÞ 1þ ðNo of connected cellsÞ 2þ ðNumber of polygonsÞ 3
Total number of cells

þ ½0; 1 or 2
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2-ME1 tissue levels in regressing CL compared with the late
luteal phase (P< .05) (Fig. 1D). Conversely, the highest tis-
sue levels of 4-OHE1 were detected in mid-luteal phase CL.
On the other hand, the highest 16-ketoE2 tissue concentra-
tions were observed in early luteal phase CL (P< .05). Both
EM tissue levels decreased significantly in the late luteal
phase CL compared with the early or mid-luteal phase
(P< .05). Administration of hCG in doses of 10,000 IU IM
restored the tissue concentration of both EMs in the late
luteal phase tissue. Figure 1F shows that the ratio of 4-
OHE1 and 16-ketoE2 vs. 2-ME2 and 2-ME1 metabolites is
significantly higher in the mid-luteal phase, and after
in vivo administration of hCG as compared with late luteal
phase CL. The 4-OHE1 and 16-ketoE2 metabolites decreased
significantly in the late luteal phase CL, but hCG increased
the tissue concentrations of these metabolites (P< .001).
These data suggest a functional role for catecholestrogen
and methoxyestrogens in CL development and regression,
respectively.
Effect of EMs on LGCs VEGF Production and
Angiogenic Activity
Concentrations of VEGF in CM of LGC cultures increased
significantly in the presence of hCG (10 IU/mL) and declined
in the presence of 2-ME1 compared with basal levels (P< .05).
2-Methoxyestrone decreased VEGF levels in the presence of
hCG, but this reduction was not statistically significant
(Fig. 2A). Figure 2B illustrates the angiogenic activity of
LGC cultures. Human chorionic gonadotropin significantly
augments the angiogenic activity of the CM (P< .05).
2-Methoxyestrone treatment significantly reduced tube for-
mation (P< .05). Interestingly, hCG prevents the reduction
in tube formation. These data suggest that 2-ME1 does not
affect hCG-induced angiogenesis. Figure 2C shows the
increasing effect of 4-OHE1 and 16-ketoE2 on VEGF secretion
compared with basal levels. Both metabolites increased
significantly the tube formation (P< .05), the proangiogenic
effects 4-OHE1 and 16-ketoE2 are similar, and their combina-
tion did not have a synergistic proangiogenic affect alone or
in the presence of hCG (Fig. 2D). These findings suggest an
important role for these metabolites in the formation and
development of the CL.
Figure 3 illustrates the expression of enzymes involved in
methoxyestrogen formation, P4501A1 and COMT, throughout
the luteal phase and after administration of hCG. Protein
expression of P4501A1 and COMT, determined by Western
blotting, did not differ among CL of different ages. However,
the abundance of P4501A1 and COMT increased significantly
after IM administration of 10,0000 IU hCG as compared with
late luteal phase CL (P< .05). This indicates that hCG regulates
enzymes involved in the production of EMs.
Figure 4A depicts the localization of VEGF in CL of
different ages and after administration of hCG. The staining
for VEGF was predominantly localized in granulosa cells of
the CL. The staining in theca–lutein cells of the CL is almost
negligible. Figure 4B depicts the VEGF levels evaluated by
expression level score (ELS) in LGCs and endothelial cells of
early, mid-, and late luteal phase CL and late CL plus hCG
compared with early and late luteal phase CL (P< .05).
FIGURE 1
Tissue levels of E2, E1, P, 2-ME2, 2-ME1, 16-ketoE2, and 4-OHE1 in the CL throughout the luteal phase and after administration of hCG. (A) Estradiol
in different stages of the luteal phase (P>.05). (B) Mid-luteal E1 vs. late (
aP%.01). (C) Late luteal P vs. early, mid-, and late plus hCG (bP<.01). (D) Late
luteal 2-ME2 and 2-ME1 vs. mid- and late plus hCG (
d,eP<.05). (E) Late luteal 16-ketoE2 and 4-OHE1 vs. mid- and late plus hCG (
c,fP<.05). (F) Ratio of
16-ketoE2 and 4-OHE1 vs. 2-ME2 and 2-ME1 metabolites. Early luteal vs. mid- and late vs. late plus hCG (
g,hP<.001). n ¼ 5 per CL stage.
Henríquez. Estrogen metabolites and CL angiogenesis. Fertil Steril 2016.
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FIGURE 2
Effect of EMs on VEGF production and angiogenic activity by LGC cultures. (A) 2-Methoxyestrone reduced VEGF production by LGCs compared
with basal conditions (bP<.05), whereas hCG increased VEGF levels (aP<.05). (B) Human chorionic gonadotropin increased the angiogenic
activity (cP<.05), whereas 2-ME1 partially reduced tube forming induced by hCG (dP>.05). (C) 16-Ketoestradiol and 4-OHE1 increased VEGF
production by LGCs compared with basal conditions (eP<.05). (D) Both EMs increased tube formation compared with basal conditions
(fP<.05). (E) Photomicrograph of the angiogenic assay.
Henríquez. Estrogen metabolites and CL angiogenesis. Fertil Steril 2016.
FIGURE 3
Expression of COMTand P4501A1 in CL collected during the luteal phase and after administration of hCG. (A, B) Western blotting for P4501A1 and
COMT. Protein expression of P4501A1 and COMT did not differ between CL of different ages. In vivo hCG administration enhanced expression
(*P<.05, n ¼ 5).
Henríquez. Estrogen metabolites and CL angiogenesis. Fertil Steril 2016.
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DISCUSSION
The human CL is an endocrine gland characterized by signif-
icant angiogenic and steroidogenic activity in both the
normal menstrual cycle and during early pregnancy (1). The
molecular and cellular machinery controlling angiogenesis
and steroidogenesis is largely regulated by LH or hCG (21,
22). It is thought that VEGF, connective tissue growth
factor, and the insulin growth factor (IGF) systems are also
involved in the regulation of luteal function and
angiogenesis (23–25). Interestingly, very recently we
reported that 2-ME2 produced by luteal cells may play a
role in physiologic luteolysis by reducing luteal angiogenesis
(16). However, 2-ME2 is not the only EM produced by the CL
that may have biological functions that are not associated
with their parent hormones, E2 and E1. Because of the limited
understanding of the role of EM in human luteal function, the
aim of the present study was to determine whether other EMs
produced by the human CL are involved in luteal angiogenesis
and function. Previous reports suggest that swine granulosa
cells cultured under restricted oxygen conditions produce
FIGURE 4
Immunohistochemistry of VEGF throughout the luteal phase and after administration of hCG. (A) Photomicrographs depict luteal tissue collected
during the early, mid-, late, and late plus hCG luteal phase stained for VEGF. (B) The immunohistochemistry signal is prominent in luteal cells of the
mid-luteal phase CL and after hCG administration compared with the early and late luteal phase CL (a,bP<.05, n ¼ 5).
Henríquez. Estrogen metabolites and CL angiogenesis. Fertil Steril 2016.
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increased amounts of 2-ME2, which may explain the reduc-
tion in VEGF in vitro. The mechanism presumably involves
the regulation of hypoxia-inducible factor 1a expression.
Interestingly, this inhibitory effect was reversed by hCG (26,
27). It is tempting to speculate that the increasing
expression of hypoxia-inducible factor 1a in cells exposed
to hypoxia fails to activate VEGF transcription in the presence
of methoxyestrogens. This physiologic setting of hypoxia
could be present during CL regression. Consequently, we
analyzed a spectrum of these molecules, including keto, hy-
droxylated, and methylated EMs, in CL tissue of different
ages. The selection of the EMs potentially involved in luteal
function was based on their concentrations in luteal tissue
of different ages and on reports in the scientific literature
(28–30).
The second aim of this investigation was to examine
in vivo and in vitro the effect of EMs and hCG on the steroido-
genic competence and angiogenic potential of granulosa–
lutein cells. It is well known that the early and mid-luteal
phase human CL is a site of a rich vascular network essential
for P biosynthesis (21). It is thought that LH and VEGF play a
critical role in luteal vasculature development (31). Our data
indicate that the luteal levels of 16-ketoE2 were greater in
early luteal phase CL. Thus, it is conceivable that 16-ketoE2
may play a significant role in the vascular development of
early luteal phase CL because it increases tube formation ac-
tivity of EA.hy 926 cells. This proangiogenic effect of 16-
ketoE2 could partially be explained by our experimental
data that demonstrate an increase of VEGF synthesis. The
lack of a synergistic effect between hCG and 16-ketoE2 on
angiogenic activity may suggest that both compounds use
the same signaling pathways. Mid-luteal phase tissue showed
a significant increase in 4-OHE1 as compared with early luteal
phase CL. Interestingly, both 16-ketoE2 and 4-OHE1 have
similar effects on VEGF secretion and angiogenic activity.
In our initial study we discovered that 2-ME2 was a prom-
inent EM in late luteal phase tissue, potentially playing an
important role in physiologic luteal regression. In the present
study we found that other members of the methoxyestrogens
family, including 2-ME1, are significantly elevated in late
luteal phase tissue in association with a significant reduction
of VEGF secretion and angiogenic activity. Similar effects of
both methoxiestrogens and concentration changes in late
luteal CL suggest their participation in CL regression during
nonconception cycles. Taken together, these new findings
on EMs indicate that they may be important players in
ovarian physiology. The ratios of EMs with proangiogenic
and antiangiogenic action were determined throughout the
normal luteal phase suggest a finely tuned paracrine effect
at the time of implantation and CL regression. An additional
important finding was derived from the in vivo study of the
acute effects of hCG, which caused a significant reduction
of 2-ME2 and 2-ME1 in late luteal phase tissue, with a parallel
increase in VEGF and the pro-angiogenic EMs 16-ketoE2 and
4-OHE1.
P4501A1 and COMT are critical enzymes in EM produc-
tion (32). In our previous study the abundance of these en-
zymes determined by Western blot did not change
significantly in the CL throughout the luteal phase (16). In
contrast, in the present study, the in vivo IM administration
of 10,000 IU of hCG significantly increased the expression
of P4501A1 and COMT enzymes 24 hours after hCG adminis-
tration. The increase in P4501A1 abundance may support the
rise of the proangiogenic EMs like 16-ketoE2 and 4-OHE1 that
presumably contribute to support the CL vascular network
(30). However, the increase in COMT abundance promoted
by hCG is not consistent with the reduction of 2-ME2 and
2ME1 concentrations in the late luteal phase CL. This apparent
discrepancy may reflect the role of COMT in other metabolic
activities, or perhaps alterations in other enzymes involved
in EM processing that would divert substrate away from
COMT, such as enzymes responsible for estrogen sulfoconju-
gation and glucuronidation, consequently reducing the levels
of catecholestrogens (33, 34).
In summary, our observations suggest novel paracrine
mechanisms, driven by different EMs, in the development
and demise of the human CL during nonconceptionmenstrual
cycles, and the late luteal phase rescue of the CL by hCG in cy-
cles of conception.
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SUPPLEMENTAL FIGURE 1
Immunodetection of StAR in cultured LGCs. (A) Immunofluorescence staining for StAR in primary culture of LGCs under basal conditions. The StAR
signal (green) is intense in the cytoplasm (mitochondria) of most cultured cells. (B) Negative control (absence of primary antibody).
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